We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Panel: Rule Out Cardiac Risks for Weight-Loss Drugs
Panel: Rule Out Cardiac Risks for Weight-Loss Drugs
April 11, 2012
An FDA advisory panel March 29 voted 17–6 to recommend requiring drugmakers to rule out cardiac risks of investigational obesity drugs, even if a theoretical risk or signal for harm is not present.